CJC-1295 w/DAC
Long-acting GHRH analog with Drug Affinity Complex for sustained GH release.
1 mg/week (standard weekly dose)
Key Benefits
albumin binding via the DAC modification extends half-life to 6–8 days, enabling true once-weekly research protocols
Phase 1/2 studies showed 1.5–3× increase in IGF-1 levels sustained for the full week between injections
covalent albumin binding is a fundamentally different mechanism from other GHRH analogs, enabling tonic rather than pulsatile GH release
sustained IGF-1 elevation supports lean mass accretion and fat oxidation over long-term research protocols
Recommended Injection Sites
Optimal injection locations for CJC-1295 w/DAC based on its route (Subcutaneous injection) and pharmacokinetic profile.
Tap a glowing zone on the body map to highlight the matching site card — or tap a card to activate the zone.
Tap a zone to inject
Preferred site for once-weekly GHRH analog dosing. Large depot ensures consistent slow release over the 6–8 day half-life.
Reliable weekly rotation site. Equivalent AUC over the extended half-life period.
Third weekly rotation site. Requires assistance for consistent placement.
Rotate weekly: abdomen → thigh → upper arm. The 6–8 day half-life means each site gets 2–3 weeks of rest between injections in a 3-site rotation.
- IV administration
- Intramuscular injection (significantly alters PK profile)
- Lipodystrophic tissue
Active Signaling Pathway
CJC-1295's Drug Affinity Complex (DAC) covalently binds albumin, extending half-life to 6–8 days. This creates tonic (continuous) rather than pulsatile GH elevation, producing sustained IGF-1 increases throughout the week.
Recommended Stacks
CJC-1295 w/DAC is a key compound in these curated research stacks. Pair it with synergistic peptides for enhanced outcomes.
GH Axis Optimization
Maximize growth hormone output with a dual GHRH approach for serious body composition research.
How long will one vial last?
Based on standard research protocols, here's exactly what to expect from a single 5mg vial — and when to plan your next order.
Actual duration may vary based on your specific protocol. Always consult your research guidelines for precise dosing schedules.
Scientific Background
Mechanism of Action
CJC-1295 w/DAC is GHRH(1-29) modified with a maleimidoproprionic acid (MPA) Drug Affinity Complex that covalently binds to cysteine-34 on circulating albumin. This albumin binding dramatically extends the half-life from ~7 minutes (native GHRH) to 6–8 days, enabling once-weekly dosing. The result is sustained, tonic GH elevation rather than the pulsatile pattern of shorter-acting GHRH analogs.
Clinical Context
CJC-1295 w/DAC produces a fundamentally different GH secretion pattern than shorter-acting GHRH analogs — sustained tonic elevation rather than pulsatile release. This makes it valuable for research comparing tonic vs. pulsatile GH signaling. The once-weekly dosing schedule simplifies long-term research protocols significantly.
Research Highlights
- Phase 1/2 studies showed 2–10× increase in mean GH concentration and 1.5–3× increase in IGF-1 after single injection
- GH elevation sustained for 6–8 days post-injection — enables true once-weekly research protocols
- Often combined with GHRP-2 or GHRP-6 in research stacks for synergistic GH pulse amplification
- Sustained IGF-1 elevation (vs. pulsatile) may have different downstream effects on tissue growth and metabolism — active research area
Storage & Reconstitution
The DAC modification allows once-weekly dosing. Often stacked with GHRP compounds in research protocols.